Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Inclusion Criteria: * The patient or patient's legal guardian must provide written informed consent prior to any protocol-related procedures being performed. * The patient must have successfully completed Study ALID-003-99 (who received 21 of 26 consecutive weekly infusions). * The patient has not experienced any safety issues that would contraindicate participation in the Extension study. * A female patient of childbearing potential must have a negative pregnancy test at entry Exclusion Criteria: * The patient is pregnant or lactating. * The patient has received an investigational drug within 30 days prior to the study enrollment. * The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities